Kala Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call
November 04 2019 - 4:30PM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the development and commercialization of
therapeutics using its proprietary AMPPLIFY™ mucus-penetrating
particle (MPP) Drug Delivery Technology, today announced that it
will report third quarter 2019 financial results on Thursday,
November 7, 2019. Management will host a conference call and live
audio webcast to discuss these results and provide a business
update at 8:00 a.m. ET.
The dial-in numbers to access the conference call are
866-300-4091 (domestic) or 703-736-7433 (international) using the
conference ID 1955939. To access a live webcast and subsequent
archived recording of the call, please visit the “Investors &
Media” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development
and commercialization of therapeutics using its proprietary
AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery
Technology, with an initial focus on the treatment of eye diseases.
Kala has applied the AMPPLIFY Drug Delivery Technology to a
corticosteroid, loteprednol etabonate (LE), designed for ocular
applications, resulting in the August 2018 FDA approval of
INVELTYS® for the treatment of inflammation and pain following
ocular surgery and its lead product candidate, KPI-121 0.25%, for
the temporary relief of the signs and symptoms of dry eye
disease.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191104006003/en/
Investor: Hannah Deresiewicz
hannah.deresiewicz@sternir.com 212-362-1200
Media: Kari Watson kwatson@macbiocom.com 781-235-3060
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024